Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

H.C. Wainwright Remains a Buy on Precigen (PGEN)

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4